With these PPPs, vaccine companies can reach agreements faster, in turn rolling out vaccines faster
Alex Knapp 21 [Alex Knapp is a senior editor covering healthcare, science, and cutting edge technology who joined Forbes in 2011. He has a B.S. in biochemistry from WPI and a J.D. from the University of Kansas School of Law; “Patent Waivers Won’t Impact Big Pharma’s Bottom Line—But Could Slow Covid Vaccine Rollouts”; Forbes; May 7 2021; https://www.forbes.com/sites/alexknapp/2021/05/07/patent-waivers-wont-impact-big-pharmas-bottom-line-but-could-slow-covid-vaccine-rollouts/]//bcp-kk
On Friday, vaccine manufacturer Novavax, which has reached an agreement with the private-public global health partnership Gavi to provid[ing] 1.1 billion vaccine doses to low income countries, stated its opposition to the WTO waiving patents, arguing that it “could further constrain resources by diverting them to entities incapable of manufacturing safe and effective vaccines in the near term.”